[1]

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, et al. 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74:229−263

doi: 10.3322/caac.21834
[2]

Han B, Zheng R, Zeng H, Wang S, Sun K, et al. 2024. Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center 4:47−53

doi: 10.1016/j.jncc.2024.01.006
[3]

Zeng H, Zheng R, Sun K, Zhou M, Wang S, et al. 2024. Cancer survival statistics in China 2019-2021: a multicenter, population-based study. Journal of the National Cancer Center 4:203−213

doi: 10.1016/j.jncc.2024.06.005
[4]

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, et al. 2020. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine 382:1894−1905

doi: 10.1056/nejmoa1915745
[5]

Ren Z, Xu J, Bai Y, Xu A, Cang S, et al. 2021. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. The Lancet Oncology 22:977−990

doi: 10.1016/S1470-2045(21)00252-7
[6]

Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, et al. 2024. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Annals of Oncology 35:448−457

doi: 10.1016/j.annonc.2024.02.005
[7]

Qin S, Chan SL, Gu S, Bai Y, Ren Z, et al. 2023. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet 402:1133−1146

doi: 10.1016/S0140-6736(23)00961-3
[8]

Zhao H, Guo Y, Li S, Han R, Ying J, et al. 2015. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget 6:31927−31943

doi: 10.18632/oncotarget.5578
[9]

Qin SK, Li Q, Xu JM, Liang J, Cheng Y, et al. 2020. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: immunodynamic biomarkers and overall survival. Cancer Science 111:4218−4231

doi: 10.1111/cas.14641
[10]

Fan Y, Li S, Ding X, Yue J, Jiang J, et al. 2019. First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. BMC Cancer 19:279

doi: 10.1186/s12885-019-5471-1
[11]

Zheng X, Gou Y, Jiang Z, Yang A, Yang Z, et al. 2021. Icaritin-induced FAM99A affects GLUT1-mediated glycolysis via regulating the JAK2/STAT3 pathway in hepatocellular carcinoma. Frontiers in Oncology 11:740557

doi: 10.3389/fonc.2021.740557
[12]

Li M, Jin R, Wang W, Zhang T, Sang J, et al. 2017. STAT3 regulates glycolysis via targeting hexokinase 2 in hepatocellular carcinoma cells. Oncotarget 8:24777−24784

doi: 10.18632/oncotarget.15801
[13]

Xin H, Zhao Z, Guo S, Tian R, Ma L, et al. 2025. Targeting the JAK2-STAT3-UCHL3-ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer. Acta Pharmaceutica Sinica B 15:2529−2544

doi: 10.1016/j.apsb.2025.03.041
[14]

Zheng D, Deng Y, Deng L, He Z, Sun X, et al. 2025. CDCA7 enhances STAT3 transcriptional activity to regulate aerobic glycolysis and promote pancreatic cancer progression and gemcitabine resistance. Cell Death & Disease 16:68

doi: 10.1038/s41419-025-07399-1
[15]

Li M, He X, Guo W, Yu H, Zhang S, et al. 2020. Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways. Nature Cancer 1:735−747

doi: 10.1038/s43018-020-0086-7
[16]

Tao QF, Yuan SX, Yang F, Yang S, Yang Y, et al. 2015. Aldolase B inhibits metastasis through Ten–Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma. Molecular Cancer 14:170

doi: 10.1186/s12943-015-0437-7
[17]

Feng J, Li J, Wu L, Yu Q, Ji J, et al. 2020. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 39:126

doi: 10.1186/s13046-020-01629-4
[18]

Hay N. 2016. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nature Reviews 16:635−649

doi: 10.1038/nrc.2016.77
[19]

Johnson DE, O'Keefe RA, Grandis JR. 2018. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology 15:234−248

doi: 10.1038/nrclinonc.2018.8
[20]

Zhang C, Hu S, Yin C, Wang G, Liu P. 2025. STAT3 orchestrates immune dynamics in hepatocellular carcinoma: a pivotal nexus in tumor progression. Critical Reviews in Oncology/Hematology 207:104620

doi: 10.1016/j.critrevonc.2025.104620
[21]

Dai Z, Ramesh V, Locasale JW. 2020. The evolving metabolic landscape of chromatin biology and epigenetics. Nature Reviews Genetics 21:737−753

doi: 10.1038/s41576-020-0270-8
[22]

Zhang D, Tang Z, Huang H, Zhou G, Cui C, et al. 2019. Metabolic regulation of gene expression by histone lactylation. Nature 574:575−580

doi: 10.1038/s41586-019-1678-1
[23]

Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, et al. 2024. Histone lactylation drives CD8+ T cell metabolism and function. Nature Immunology 25:2140−2151

doi: 10.1038/s41590-024-01985-9
[24]

Li YJ, Zhang C, Martincuks A, Herrmann A, Yu H. 2023. STAT proteins in cancer: orchestration of metabolism. Nature Reviews Cancer 23:115−134

doi: 10.1038/s41568-022-00537-3
[25]

Zhong Z, Yang K, Li Y, Zhou S, Yao H, et al. 2024. Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progression. Cancer Letters 588:216784

doi: 10.1016/j.canlet.2024.216784
[26]

Certo M, Tsai CH, Pucino V, Ho PC, Mauro C. 2021. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nature Reviews Immunology 21:151−161

doi: 10.1038/s41577-020-0406-2